MedTrace Logo

Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye

NCT02326090 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2015-09-09

No results posted yet for this study

Summary

The objective of the Phase 2 study is to compare the safety and efficacy of cis-UCA Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.

Conditions

  • Dry Eye Syndrome

Interventions

DRUG

cis-UCA ophthalmic solution 1.0%

DRUG

cis-UCA ophthalmic solution 2.5%

DRUG

Placebo ophthalmic solution

Sponsors & Collaborators

  • ORA, Inc.

    collaborator INDUSTRY

  • Herantis Pharma Plc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02326090 on ClinicalTrials.gov